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Abstract
Background: In recent few years is underlined that altered balance of pro- and anti-inflammatory cytokines play
an important role in the pathogenesis of AITD.
The aim of this study was to estimate intracellular INF-g and IL-4 levels in thyroid-infiltrating lymphocytes and
thyrocytes isolated from thyroid tissues in 54 adolescent patients aged 8-21 years, with Graves’ disease (GD; n =
18), Hashimoto’s thyroiditis (HT; n = 18) and non-toxic multinodular goiter (NTMG; n = 18).
Methods: Fresh thyroid tissues were taken on culture medium RPMI -1640, it was mechanically prepared. In next step
were added cell activators -12- myristate 13- the acetate (PMA) and Ionomycin as well as the inhibitor of transportation
of proteins - Breferdin A. They were cultured 24 hours in 50 ml flasks at 37°C in a 5-95% CO2-air water-saturated
atmosphere. After that, thyrocytes were identified by mouse mAb directed against human TPO epitope 64 conjugated
with rabbit anti-mouse antibodies IgG (Fab’)2 labeled by FITC. After incubation at room temperature to each of samples
added reagent A fixative the cellular membrane. In next step into the cell suspensions were added reagent B to
permeabilization of cellular membrane and specific anti-IL-4-PE or anti-IFN-g-PE mAbs. Identification of intracellular
cytokines in T lymphocytes was performed in the same procedure with application of anti-CD4-PerCP and anti-CD8-
PerCP mAbs specific for T lymphocytes. The cells were analyzed in a flow cytometry (Coulter EPICS XL).
Results: In examined group of patients with GD we observed statistically significant higher mean percentage of
cells with phenotype CD4+IL-4 (p < 0.05; p < 0.025), CD8+IL-4 (p < 0.033; p < 0.01) and TFCs-IL-4+ (p < 0.05; p <
0.01) in comparison to patients with HT and NTMG. The analysis of mean percentages of positive TILs and TFCs
with intracellular INF-g levels in patients with HT revealed statistically significant increase percentage of CD4+INF-g
(p < 0.04; p < 0.001), CD8+ INF-g (NS; p < 0.025), TFCs+INF-g (p < 0.03; p < 0.001) cells in comparison to the
percentage of positive cells from patients with GD and NTMG.
Conclusions: We conclude that human thyrocytes in autoimmune thyroid disorders could be a source of cytokine
production and that their activation influences local interaction with T lymphocytes inflowing to the thyroid gland.
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Background
Graves’ disease (GD) and Hashimoto’s thyroiditis (HT)
are a common autoimmune disorders. It was proven,
that subpopulation of Th1 plays an important role in
induction of classical mechanisms of late type reaction
and that produced by CD4+ IFN-g is an activator of
macrophages and stimulates production of IgG2a. Th1
cells through the influencing on differentiation of cyto-
toxic lymphocytes CD8+, modulate also inflammatory
reaction in response to the antigen stimulation [1]. CD4+
cells, which belong to subpopulation Th2 stimulate immu-
nological response of B lymphocytes. There are some stu-
dies evaluating cytokines in these diseases, demonstrating
the production of IL-4 and TNF- by infiltrating T cells
and macrophages. However, the specific role of these
molecules in the pathogenesis of autoimmune thyroid
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altered balance of pro- and anti-inflammatory cytokines
may play an important role in the pathogenesis of autoim-
mune thyroiditis.
T-helper 1 (Th1) cell-mediated inflammatory
responses predominate in the early pathogenesis of GD,
whereas Th2 cell-mediated immunity may play a role in
later stages. Th1 cells produce IFN-gamma and Th2
cells produce IL-4. Nanba T et al. reported that IFN-
gamma and IL-4 gene polymorphisms, which are related
to higher IFN-gamma and lower IL-4 production,
respectively, are more frequent in patients with severe
HT than in those mild HT. They investigated the
proportion of peripheral Th1 and Th2 cells in patients
with AITD and concluded that the peripheral Th1/Th2
cell ratio is related to the severity of HT and is related
to the intractability of GD. They hypothesize that these
patterns of peripheral Th cell subsets may be expressed
within the thyroid [5].
The aim of this study was to estimate intracellular
INF-g and IL-4 levels in thyroid-infiltrating lymphocytes
(TILs), and in thyroid follicular cells with application of
mouse monoclonal antibodies type #64 which recognize
B antigen regions of TPO (thyroid peroxidase) in
patients with AITD and NTMG.
Patients and methods
The study was performed in a group of 54 adolescent
patients (14 boys and 42 girls), aged 8-21 years, with
Graves’ disease (GD; n = 18, mean age 16.4 ± 3.3 years),
Hashimoto’s thyroiditis (HT; n = 18, mean age 16.8 ±
2.8 years) and non-toxic multinodular goiter (n = 18,
mean age 16 ± 3 years), hospitalized in the Department
Pediatrics, Endocrinology, Diabetology with the Cardiol-
ogy Division, Medical University of Białystok. The
patients underwent total or subtotal thyroidectomy in
the 1st Department of General Surgery, Medical Univer-
sity of Białystok or in the Department of Pediatric Sur-
gery, Traumatology and Urology, Poznań University of
Medical Sciences. The diagnosis was established based
on clinical examinations confirmed by laboratory, ultra-
sonographic and scintigraphic investigations with the
use of
131I (in case of nodular goiter with symptoms of
hyperthyroidism). Additionally, fine-needle aspiration
biopsies in HT and nodular goiter were performed in
the Department of Patomorphology, Medical University
of Białystok. The qualifying criteria for patients with GD
were as follows: large goiter, presence of ophthalmopa-
thy, antibodies against receptor for thyroid stimulating
hormone (TRAb) > 5, positive titers of antithyroid
peroxidase (anti-TPO) or anti-thyroglobulin (anti-TG)
antibodies, and persisting over 2-3 months since the diag-
nosis of thyroid- stimulating hormone (TSH) < 0.45.
Methimazole therapy, at the initial dose of 0.5-1.0 mg/kg/
day, was used in combination with propranolol 0.5-1.0
mg/kg/day to treat hyperthyroidism in the course of GD.
A further reduction in methimazole dose and obtaining
euthyrosis prior to surgery depended on clinical-biochem-
ical parameters. Average daily doses of this antithyroid
drug were 10-15 mg. Patients with HT received treatment
exclusively with L-thyroxine (mean 75 ± 25 mg/24 h) for
the period of 6-12 months (mean 8 months) since the
diagnosis.
The function of the thyroid gland in patients with GD
w a sa s s e s s e da tt h et i m eo fd i a g n o s i sa n dp r i o rt os u r -
gery. Thyroid function was evaluated based on thyroid
hormones and TSH tests performed jointly with the
measurement of titers of antithyroid antibodies (ATPO,
ATG, TRAK).
Our study was approved by the Committee for Ethics
and Supervision on Human and Animal Research of the
Medical University in Białystok. An informed consent
was given by the participating children and their
parents.
Determination of the Antithyroid Antibody Titers and
Thyroid Hormone Concentration
Blood for analysis was collected on empty stomach in
the morning hours from the basilic vein and centrifuged
for 10 min at 2,000 rotations/min. Sera were stored at
-20° until the required number was collected. Thyroid
stimulating hormone receptor antibodies (TRAbs) were
routinely determined by a radioreceptor assay (TRAK-
human kits, Brahms Diagnostica GmbH, Berlin, Ger-
many), in which the value < 1 U/l was treated as nega-
tive, 1.0-1.5 U/l as a grey zone and the values > 1.5 U/l
were considered positive. Antithyroperoxidase antibodies
(TPO-Abs) and antithyroglobulin antibodies (TG-Abs)
were determined using immunodiagnostic test Varelisa
(Variable Enzyme Linked Immno Sorbent Assay,
Pharmacia
Upjohn Diagnostics GmbH Co.KG. Freiburg,
Germany). Normal range for TG-Abs was < 500 IU/ml
and for TPO-Abs was < 50 IU/ml. The levels of fT4, fT3
and hTSH in blood serum were determined on a mini-
analyzer (Bio Merieux, France), based on test VIDAS (Bio
Merieux, France), combining the immunoenzymatic
method with the final fluorescence measurement (ELFA).
Normal range of fT4 was 0.71-1.55 ng/dl, fT3–2.6-5.4
ng/dl and hTSH–0.32-5.0 μIU/ml.
Thyrocyte preparations
The thyroid tissue samples were analyzed following the
previously described techniques [6,7]. Briefly, postopera-
tive 1.0 cm/1.0 cm thyroid sections were collected to
test-tubes with RPMI-1640 medium. Initially, the mate-
rial was minced mechanically and digested with a mix-
ture of collagenase type IV-S (Sigma) in Hanks balanced
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Page 2 of 9saline solution (HESS). To eliminate non-adherent cells
from thyrocyte preparations, the dispersed cells were
cultured for
24 h with minimum essential medium (MEM), con-
taining 10% fetal bovine serum and Ham F12 medium,
supplemented with 20 mm HEPES buffer, 2 mm L-glu-
tamine, 100 U/ml penicillin, and 100 μg/ml streptomy-
cin (Sigma). They were cultured in 50 ml flasks (Falcon
Plastics, Becton-Dickinson, USA) at 37°C in a 5-95%
CO2-air water-saturated atmosphere. The following day,
the non-adherent cells (predominantly lymphoid cells
and erythrocytes) were removed from culture superna-
tants for lymphocyte isolation. Trypsinization was per-
formed at confluence (Figure 1).
Identification of thyrocyte populations
Purity of thyroid cells was tested by flow cytometry as
previously described [7]. Briefly, the isolated cells diluted
in RPMI 1640 medium were rinsed twice with a buffer
containing PBS, 0.5% bovine albumin and 2 mM EDTA,
and suspended in 1 ml PBS. After that, 50 μl portions of
cell suspension were placed in a test-tube, adding 10 μl
of mouse monoclonal antibody (mAb) at 400 μg/ml
concentration directed against human TPO epitope 64
reacting with domain B. Following 30 min incubation at
4°C, the cells were rinsed three times with a buffer of
PBS + 0.5% bovine albumin + 2 mM EDTA. Then, 20
μl of rabbit antibody F(ab’)2 conjugated with FITC
(FITC-coupled F(ab’)2 antimouse IgG, DAKO) was
added. After 30 min incubation at 4°C, cell suspensions
were rinsed three times again in the buffer described
above. Then, the samples were submitted to analysis in
a flow cytometer (Coulter EPICS XL).
The unspecific binding of monoclonal antibodies to
the thyrocytes was evaluated by the use of irrelevant
IgG of the same isotype as the used antibodies. The spe-
cificity of the reaction was checked by immunoprecipita-
tion of mAbs by highly purified human TPO.
Identification of intracellular IL-4 and IFN-g levels in
thyrocytes by flow cytometry
Fresh thyroid tissues were taken on culture medium
RPMI -1640, it was mechanically preparated (described
as above). Briefly, the cell suspensions were rinsed three
times with PBS, and later were added cell activators - 12
- myristate 13 - the acetate (the PMA - 50 ng/ml) and
Ionomycin (1 mM) as well as the inhibitor of transpor-
tation of proteins - Breferdin A (3 mmol/ml). They were
cultured 24 hours in 50 ml flasks at 37°C in a 5-95%
CO2-air water-saturated atmosphere. After that, 10 μlo f
mouse monoclonal antibody (mAb) directed against
human TPO epitope 64 was added into the suspension.
After 15 minutes of incubation at room temperature to
each of samples added 100 μl of reagent A fixative the
cellular membrane (IntraStain-Dako, Denmark). In next
step we conjugated this complex with rabbit anti-mouse
antibodies IgG (Fab’)2 labeled by FITC and than incu-
bated by next 15 minutes (identified as above). Then,
the cell suspensions were rinsed three times with PBS
and were added 100 μl of reagent B to permeabilization
the cellular membrane (IntraStain-Dako, Denmark) and
20 μl specific anti-IL-4-PE (IgG1, BD) or anti-IFN-g-PE
(IgG1, BD) monoclonal antibody, and murine IgG1 as
negative control, then incubated for 30 min at 4°C.
After two washes with PBS supplemented with 5% BSA,
the cells were immediately analyzed in a flow cytometry
(Coulter EPICS XL) (Figure 2, Figure 3).
Identification of intracellular IL-4 and IFN-g levels in
lymphocyte populations by flow cytometry
The percentage of lymphocytes was determined as pre-
viously described [8]. Briefly, after 24 h of incubation
with cell activators and inhibitor of transportation of
proteins (described above), the non-adherent cells (pre-
dominantly lymphoid cells and erythrocytes) were
removed from culture supernatants for lymphocyte iso-
lation. In the next step, 10 μl anti-CD4-PerCP and anti-
CD8-PerCP (IgG1, BD) monoclonal Abs were used for
(a)        
(b)     
Figure 1 Thyrocytes in suspension in culture medium (a)
formed monolayers on plastic plates after 24 h in culture (b).
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lymphocytes. After 15 minutes of incubation at room
temperature to each of samples added 100 μlo fr e a g e n t
A fixative the cellular membrane (IntraStain-Dako, Den-
mark) and incubated by next 15 minutes. Then, the cell
suspensions were rinsed three times with PBS and were
added 100 μl of reagent B to permeabilization the cellu-
lar membrane (IntraStain-Dako, Denmark) and 20 μl
specific anti-IL-4-PE (IgG1,B D )o ra n t i - I F N - g-PE (IgG1,
BD) monoclonal antibody, with murine IgG1 as negative
control. The cells were analyzed in a flow cytometry
(Coulter EPICS XL).
Statistical analysis
The results were analyzed using Statistica 9.0 software.
The mean values of immune parameters between groups
were evaluated using Student’s t test, U Mann-Whitney’s
test or Fisher’s exact probability test. Correlation was
assessed by Spearman’ss i g n e dr a n k st e s t .P<0 . 0 5w a s
considered significant.
Results
Table 1 presents the characteristics and laboratory find-
ings in patients with GD (prior to methimazole treat-
m e n ta n dt h e ni nt h es t a t eo fc l i n i c o - b i o l o g i c a l
euthyrosis before surgery), with HT and with nontoxic
nodular goiter (NTMG; prior to treatment). Patients
with > 1 cm nodular lesions in ultrasonography under-
went fine-needle aspiration biopsy (BAC), which showed
benign colloid nodular goiter. Scintigraphy additionally
performed in 3 patients with nodular goiter and clinical
symptoms of hyperthyroidism showed a selective
a)                                                                                    b)       
 
 
IL-4  IL-4 
Figure 2 Identification of IL-4 in thyroid follicular cells in patients with GD and HT using flow cytometry. (a) Flow cytometric dot plots of
dispersed TFCs from a representative patient with GD. Scatter plot of gating thyrocytes (left upper panel). Flow cytometric detection of IL-4 in
thyrocytes from patients with GD (left down panel). Cells were labeled with control IgG1 (grey) or anti-IL-4 mAb (white). (b) Flow cytometric dot
plots of dispersed TFCs from a representative patient with HT. Scatter plot of gating thyrocytes (right upper panel). Flow cytometric detection of
IL-4 in thyrocytes from patients with HT (right down panel). Cells were labeled with control IgG1 (grey) or anti-IL-4 mAb (white).
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the area of single nodular lesions.
In the analysis of the thyroid peroxidase antigen by
flow cytometry method, anti-human native TPO mouse
monoclonal antibodies were used. The assessment of
the percentage of thyroid cells with mAb #64TPO epi-
tope expression showed no significant differences
between GD and HT patients (73 vs.65%, NS) at a con-
centration of 400 mg/ml of anti-TPO antibodies. When
the concentration of anti-TPO antibodies decreased, the
mean percentage of thyroid cells with antigen region
#64 expression was reduced.
Patients with GD showed a higher percentage of CD4
+IL-4, CD8+IL-4 and TFC-IL-4+ cells, compared to
patients with HT (p < 0.05, p < 0.033, p < 0.05, respec-
tively) and NTMG (controls) (p < 0.025, p < 0.01, p <
0.01, respectively) (Figure 4). There was no difference
between the proportions of these CD4+IL-4, CD8+IL-4
and TFC-IL-4+ cell populations in cases with HT and
NTMG.
The analysis of mean percentages of positive TILs
and TFCs with intracellular INF-g levels in patients
with HT revealed statistically significant increase per-
centage of CD4+INF-g,C D 8 +I N F - g,T F C + I N F - g cells,
compared to the percentage of positive cells from
patients with GD (p < 0. 04, NS, p < 0.03, respectively)
and NTMG (p < 0.001, p < 0.025, p < 0.001, respec-
tively) (Figure 5).
In the present study, the relationship between antith-
yroid antibodies and the percentage of TFCs and T cells
with the expression of cytokines was evaluated. In
patients with untreated GD there was a statistically sig-
nificant positive correlation between the percentage of
TFCs-IL4+ and CD4+IL-4 T cells and the concentration
of TRAK antibodies (R = 0.62, p < 0.02; R = 0.34, p <
0.04, respectively). However, no such correlations were
a)                                                                       b) 
INF-   INF-  
Figure 3 Identification of INF-g in thyroid follicular cells in patients with GD and HT using flow cytometry. (a) Flow cytometric dot plots
of dispersed TFCs from a representative patient with GD. Scatter plot of gating thyrocytes (left upper panel). Flow cytometric detection of INF-g
in thyrocytes from patients with GD (left down panel). Cells were labeled with control IgG1 (grey) or anti-INF-g mAb (white). (b) Flow cytometric
dot plots of dispersed TFCs from a representative patient with HT. Scatter plot of gating thyrocytes (right upper panel). Flow cytometric
detection of INF-g in thyrocytes from patients with HT (right down panel). Cells were labeled with control IgG1 (grey) or anti-INF-g mAb (white).
Bossowski et al. Thyroid Research 2011, 4:13
http://www.thyroidresearchjournal.com/content/4/1/13
Page 5 of 9Table 1 Data of patients with GD before methimazole therapy, after six months of therapy (prior to surgery) in
non-toxic multinodular goiter and HT
Untreated GD group
Group A
Group after six months of
methimazole therapy
Group A’
Group with HT
Group B
Group with non-toxic
multinodular goiter
Group C
P
Age (years) 15.4 ± 2.1 16.4 ± 3.3 16.8 ± 2.8 15.8 ± 1.8 NS, NS*, NS**
n 18 18 18 18
Weight (kg) 57 ± 11.0 59 ± 7 63 ± 8 62 ± 7 NS, NS*, NS**
Height (cm) 166 ± 3 169 ± 1 170 ± 5 169 ± 7 NS, NS*, NS**
BSA (m
2) 1.66 1.68 1.7 1.67 NS, NS*, NS**
anti-TPO (IU/ml) 1250 ± 350 650 ± 250 1550 ± 500 41.3 ± 38 p < 0.0001,
p* < 0.01,
p** < 0.001
anti-TG (IU/ml) 630 ± 262 360 ± 40 820 ± 150 180 ± 86 p < 0.001,
p* < 0.01,
p** < 0.001
TRAb (U/l) > 5 positive > 3 positive (-) (-)
fT4 (ng/dl) 5.9 ± 2.0 2.04 ± 0.3 1.29 ± 0.2 1.1 ± 0.2 p < 0.001, NS*,
NS**
fT3 (ng/dl) 8.85 ± 2.1 3.8 ± 0.5 3.64 ± 0.21 2.94 ± 0.21 p < 0.002, NS*,
NS**
TSH
(μIU/ml)
0.03 ± 0.01 1.3 ± 0.2 3.1 ± 0.5 2.9 ± 0.3 p < 0.001
p* < 0.01, NS**
GD- Graves’ disease HT- Hashimoto’s thyroiditis NTMG-non-toxic multinodular goiter
p, Statistical significance between group A and C; p*, statistical significance between group A’ and C; p**, statistical significance between group B and C;
X, standard deviation; NS, no statistical significance.
**p<0.05 
p<0.01 
Figure 4 Mean percentages of positive TFCs and TILs with intracellular expression of IL-4 in examined patients.
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tinodular goiter. There were no significant correlations
between thyroid hormones and the percentage of
intrathyroid lymphocytes and TFCs with IL-4 and INF-g
expression.
Discussion
An altered balance of pro- and anti-inflammatory cyto-
kines is thought to play an important role in the patho-
genesis of autoimmune thyroid diseases. Disruption of
thyroid self tolerance, usually after an infection, gener-
ates abnormal thyroid-immune interactions, implicating
an array of cytokines and their receptors. Thyrocytes
achieve antigen presenting cell properties, which stimu-
late effectors immune cells: Th1 and Th2, in the context
of defective immunomodulatory T regulatory cells,
resulting in thyroid lymphocytic infiltration and activa-
tion of B cells, with production of antibodies against
thyroid antigens, thyroid destruction or stimulation,
depending on the Th1-Th2 balance [9].
Over the last decade many researchers have proven,
that T cell recognition of autoantigens had shown con-
siderable intra- and interindividual heterogeneity, and a
mixed pattern of cytokine production indicates that both
the Th1 and Th2 limbs of the helper T cell response are
involved in all types of autoimmune thyroiditis. HT
glands activate T cells that display a predominantly
Th1 phenotype. The Th1 pattern produces IL-2, IFN-g,
and TNF-a, with a relative absence of IL-4 or -10, sug-
gesting that these cells support a predominantly T cell-
mediated induction of apoptosis [10]. In contrast, GD
thyrocytes do not undergo apoptosis and are character-
ized by a predominantly Th2 infiltrate [11]. The Th2 pat-
tern produces relatively less IL-2, TNF- a,a n dI F N -g,
and more IL-4, -5, and -10, indicating a tendency toward
B-cell maturation and an antibody-mediated immune
response [10].
Secretion of cytokines within the thyroid accounts for
the accumulation and expansion of the intrathyroidal
lymphocyte pool. Also, the thyroid cells themselves con-
tribute to this secretion. The thyroid cells also produce
a number of proinflammatory molecules which will tend
to exacerbate the autoimmune process, eg. IFN- g and
IL-4 [12].
IFN- g, a prototypic proinflammatory cytokine pro-
duced by several different cell types, including the Th1
subset of CD4(+) T cells, plays an important role in
inflammation and autoimmune diseases [13]. Carella C
et al. observed that INF- g is the cytokine most clearly
associated with AITD, especially hypothyroidism, despite
being neither Th1- nor Th2-dependent [14]. Phenekos C
et al. found that patients with HT had higher INF- g
levels compared to patients with TNG, GD and controls.
In contrast, patients with GD had higher serum levels of
IL-4 in comparison with patients with HT. These results
were similar to the results of our study. Therefore, we
J
**p<0.03 
Figure 5 Mean percentages of positive TFCs and TILs with intracellular expression of INF-g in examined patients.
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response characteristic of cellular immunity is dominant
in HT, whereas the predominance of Th2 cytokines in
GD indicates a humoral pattern of immune reaction
[15].
IL-4 is produced by Th2, mastocytes and basophiles.
The IL-4 is involved in both humoral and cellular
immunity. Chen RH et al. tested whether the IL-4 gene
could be used as a genetic marker to predict the devel-
opment of AITD among the Chinese population of Tai-
wan. They found no significant difference in the
frequencies of presence of genotype and allelic variants
for the IL-4 gene at both the intron 3 and the promoter
regions between the normal control group and each of
the two patient groups. These findings suggest that the
IL-4 gene polymorphisms that arise at either intron 3 or
promoter -590 positions are not suitable genetic mar-
kers for AITD among Taiwanese Chinese [16].
Because GD and HT are a common autoimmune dis-
orders with genetic predisposition, the expression of
genes coding cytokines was measured. Zhu W et al.
observed strong evidence that the Chr.5q31-33 region,
which contains the immune response various cytokine
genes eg. IL-4, is linked to autoimmune thyroid disor-
ders in Chinese and Japanese populations [17]. Also
Khalilzadeh O et al. observed the association between
GD and the polymorphisms in anti-inflammatory cyto-
kine IL-4 [18].
Alnaqdy A et al. noticed that patients with GD
showed significantly higher levels of IL-4 and IFN- g
compared with the normal controls. There was also a
significant increase in serum levels of IL-4 in the treated
group, compared to the untreated group. IL-4, and IFN-
g, showed a high prevalence in Omani patients with GD.
Thus, cytokines and autoantibodies may prove useful in
the diagnosis of GD and in assessing prognosis [19].
Worth emphasizing is fact, that IL- 4 in GD prevents
adhesion molecules expression in order not to damage
thyrocytes. In our study production of IL-4 in thyrocytes
of patients with GD was elevated, what may be responsi-
ble for protection of these cells against immune damage
or reduction of their apoptosis. Stassi G et al. suggested
that, infiltration of Th2 lymphocytes and production of
IL-4 and IL-10 by thyrocytes in patients with GD can
induce the expression of antiapoptotic molecules and
leading thyrocyte resistance to CD95-mediated apoptosis
[20]. On the other hand, in patients with HT we
detected in thyrocytes elevated level of IFN- g,w h a t
may be responsible for prolongation of inflammatory
process within thyroid gland.
In conclusion, our findings suggest that the human
thyrocytes in autoimmune thyroid disorders could be a
source of cytokine production and that their activation
influences local interaction with T lymphocytes
inflowing. The alteration of intracellular cytokine levels
in T cells within thyroid gland suggest predominance
r o l eo fT h 1i m m u n er e s p o n s ei nH T ,a n dd e v e l o p m e n t
of Th2 immune response in GD.
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